---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000148"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:31:02.945686+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M

## Summary
- Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.
- Cash and equivalents $521.9M providing runway through GD readout expected in 2027.
- Batoclimab Phase 3 TED: first readout delayed; both studies now expected to report concurrently H1 2026.
- IMVT-1402 GD study showed first-ever potentially disease-modifying therapy with 6-month off-treatment data.
- Topline results for IMVT-1402 in D2T RA and CLE expected 2026; GD, MG, D2T RA in 2027.

## SEC filing metadata
- accession: 0001764013-25-000148
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/0001764013-25-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/imvt-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000148
- JSON: https://secwatch.observer/filing/0001764013-25-000148.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.